

European Journal of Pharmacology

The EUROPEAN JOURNAL OF PHARMACOLOGY publishes full-length papers, short communications and rapid communications on the mechanisms of action of chemical substances affecting biological systems. The journal also considers short reviews (not exceeding 12 pages in print) intended to debate recent advances in rapidly developing fields that are within its scope.

Full length papers and short communications are grouped under the following headings: Molecular and cellular pharmacology, Neuropharmacology and analgesia, Behavioural pharmacology, Cardiovascular pharmacology, Pulmonary, gastrointestinal and urogenital pharmacology, Immunopharmacology and inflammation, and Endocrine pharmacology.

Manuscripts submitted to the journal are accepted on the understanding that: (1) they are subject to editor review, (2) they have not been and will not be published in whole or in part in any other journal and (3) recommendations of the Declarations of Helsinki and Tokyo, for humans, and the European Community guidelines as accepted principles for the use of experimental animals have been adhered to. The European Journal of Pharmacology will, therefore, only consider manuscripts that describe experiments which have been carried out under approval of an institutional or local ethics committee. Authors must state in the manuscript that protocol complies with the particular recommendation and that approval of their protocols was obtained.

Abridged ‘General instructions’ for authors are published at the end of each issue. Essential detailed instructions will be found in the ‘Notice to Authors’, published once yearly (for 2003, in Vol. 458, Nos. 1–2, pages v–xi).

Founded in 1967. Founding editors: David de Wied and Jacques van Rossum.

Editors: W.H. GISPEN, Utrecht (chairman) F.P. NIJKAMP, Utrecht D.H.G. VERSTEEG, Utrecht

Assistant editor: F. ENGELS, Utrecht

Honorary editor: D. DE WIED

Editorial board:

I.M. ADCOCK, London	M. ELTZE, Konstanz	R. PRZEWLOCKI, Kraków
C. ADVENIER, Paris	M. ENDOH, Yamagata	P.R. SAXENA, Rotterdam
J.M. BAEYENS, Granada	E. FRIDE, Ariel	A. SCHOUSBOE, Copenhagen
L. BARTHÓ, Pécs	G.F. GEBHART, Iowa City	R. SCHULZ, München
A. BESPALOV, Saint-Petersburg	M. HAMON, Paris	P. SKOLNICK, Hackensack
G. BIGGIO, Cagliari	M. LAZDUNSKI, Valbonne	J.C. STOCLET, Strasbourg
S.D. BRAIN, London	R. LEFEBVRE, Gent	H.H.M. VAN TOL, Toronto
O.E. BRODDE, Halle	M.J. LOHSE, Würzburg	E.S. VIZI, Budapest
H. BULT, Wilrijk	W. LÖSCHER, Hannover	S.P. WELCH, Richmond
D.B. BYLUND, Omaha	J. McCULLOCH, Edinburgh	B.J.R. WHITTLE, London
F. CATTABENI, Milan	K.P. MINNEMAN, Atlanta	Z. WIESENFELD-HALLIN, Huddinge
C.H. CHO, Hong Kong	S. NAHORSKI, Leicester	J. WIKBERG, Uppsala
O. CIVELLI, Irvine	D.W. NEBERT, Cincinnati	X.-Z. ZHU, Shanghai
R. DANTZER, Bordeaux	J.M. PFEILSCHIFTER, Frankfurt	
F. DRAGO, Catania	J.P. PIN, Montpellier	

Consultants:

E. AIZENMAN, Pittsburgh; K.-E. ANDERSSON, Lund; E. BEUBLER, Graz; J. BOCKAERT, Montpellier; R. BUSSE, Frankfurt/M; S.J. COOPER, Liverpool; R. COUTURE, Montreal; G. DI CHIARA, Cagliari; G.Z. FEUERSTEIN, West Point; A.W. FORD-HUTCHINSON, West Point; J.A. GARCÍA-SÁINZ, Mexico City; A.R. GREEN, London; A. HERMAN, Antwerpen; P. HOLZER, Graz; D. HOYER, Basel; J.P. HUIDOBRO-TORO, Santiago; E.C. HULME, London; K.H. JAKOBS, Essen; H. KARAKI, Tokyo; H. KLEINERT, Mainz; K.P. LESCH, Würzburg; B.R. LUCCHESI, Ann Arbor; H. MEURS, Groningen; M.J. MILLAN, Croissy-sur-Seine; F. MORONI, Florence; T. NABESHIMA, Nagoya; M. OTSUKA, Tokyo; J.N. PENNEFATHER, Parkville; A. PERTOVAARA, Turku; R. QUIRION, Verdun; U. RAVENS, Essen; M.E.A. REITH, Chicago; H. SCHOEMAKER, Bagneux; J.F.M. SMITS, Maastricht; K. STARKE, Freiburg im Breisgau; L.A. URBAN, Basel; R.J. WINQUIST, Ridgefield

Contents continued

A novel and selective Na⁺/Ca²⁺ exchange inhibitor, SEA0400, improves ischemia/reperfusion-induced renal injury		IMMUNOPHARMACOLOGY AND INFLAMMATION
M. Ogata, T. Iwamoto, N. Tazawa, M. Nishikawa, J. Yamashita, M. Takaoka and Y. Matsumura	187	Probucol restores the defective leukocyte–endothelial interaction in experimental diabetes
The cytoprotective role of a low-molecular-weight heparin fragment studied in an experimental model of glomerulotoxicity		R.C.O. Zanardo, J.W.M.C. Cruz, L.L. Martinez, M.Ap. de Oliveira and Z.B. Fortes
P.R. Deepa and P. Varalakshmi	199	<i>Author index</i>
Effect of opioid receptor ligands on the μ-S196A knock-in and μ knockout mouse vas deferens		<i>Keyword index</i>
P.S. Portoghese, P.-Y. Law and H.H. Loh	207	

Advertising information: Advertising orders and enquiries can be sent to: **USA, Canada and South America:** Mr Tino DeCarlo, The Advertising Department, Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710, USA; phone: (+1) (212) 633 3815; fax: (+1) (212) 633 3820; e-mail: t.decarlo@elsevier.com. **Japan:** The Advertising Department, Elsevier K.K., 4F Higashi-Azabu, 1-Chome Bldg, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail: jp.info@elsevier.com. **Europe and ROW:** Commercial Sales Department, Elsevier Ltd., The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) 1865 843016; fax: (+44) 1865 843976; e-mail: media@elsevier.com

USA mailing notice: *European Journal of Pharmacology* (ISSN 0014-2999) is published weekly by Elsevier B.V. (P.O. Box 211, 1000 AE Amsterdam, The Netherlands). Annual subscription price in the USA is US\$ 9032.00 (valid in North, Central and South America), including air speed delivery. Periodical postage rate paid at Jamaica, NY 11431. **USA POSTMASTER:** Send address changes to *European Journal of Pharmacology*, Publications Expediting, Inc., 200 Meacham Ave, Elmont, NY 11003. **AIRFREIGHT AND MAILING** in the USA by Publications Expediting Inc., 200 Meacham Avenue, Elmont, NY 11003.

Printed in The Netherlands

© The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).